WHO releases Medical Product Alert for contaminated cough syrup

July 20, 2023
Medical Communications Pharmacy, WHO, cough syrups, medical product alert, world health organization

The World Health Organization (WHO) has shared a Medical Product Alert for an additional contaminated cough syrup medicine identified in …

Vaccine image

Pfizer shares new data from phase 2 trial for GBS maternal vaccine candidate

July 20, 2023
Research and Development Immunology, Pfizer, Vaccine, clinical trial

Pfizer has announced new data from its phase 2 study which assessed its hexavalent capsular polysaccharide (CPS) conjugate Group B …

Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone

July 19, 2023
Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera

Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …

Renibus Therapeutics announces $47m financing for phase 3 trial

July 19, 2023
Business Services Cardiology, Financing, Renibus Therapeutics, clinical trial

Clinical stage biopharmaceutical company Renibus Therapeutics has announced that it has raised $47m from the initial closing of its Series …

alzheimers_brain

Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment

July 18, 2023
Research and Development Alzheimer's, Eli Lilly, Neurology, clinical trial, donanemab

Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of …

1200px-vaccine_image_1_1

FDA approves AstraZeneca’s drug to prevent RSV in babies and young children

July 18, 2023
Research and Development AstraZeneca, FDA, Immunology, RSV, Vaccine, paediatrics

The US Food and Drug Administration (FDA) has announced that it has approved Beyfortus (nirsevimab-alip) for the prevention of respiratory …

Inizio Engage launches Patient Access Services – an integrated suite of patient support services to enhance access and adherence for specialty therapies

July 18, 2023
Business Services Inizio Engage, Patient Access Services, Pharmacy, patient support

Fort Washington, US — Inizio Engage is pleased to announce the launch of Patient Access Services. This custom-built, integrated suite of patient support services …

Alnylam shares positive results from phase 1 trial

July 17, 2023
Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial

Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …

Eli Lilly to acquire Versanis Bio for $1.9bn

July 17, 2023
Sales and Marketing Cardiology, Eli Lilly, Versanis Bio, acquisition, cardiometabolic diseases

Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company …

FDA approves first OTC daily oral contraceptive pill

July 14, 2023
Medical Communications Contraception, FDA, OTC, Opill, contraceptive pill

The US Food and Drug Administration (FDA) has announced that it has approved the Opill (norgestrel) tablet for nonprescription use …

Chemotherapy

EMA accepts Astellas’ MAA for Zolbetuximab

July 14, 2023
Medical Communications Astellas, Cancer, EMA, Oncology, zolbetuximab

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorisation application (MAA) for regulatory …

Recursion and NVIDIA partner for AI-enabled drug discovery developments

July 13, 2023
Research and Development AI, Pharmacy, Recursion, drug discovery

Clinical stage biotech company Recursion has announced a $50m investment by NVIDIA, intended to accelerate the development of its AI …

needle-1291170_960_720

Genentech shares results from phase 3 trial for MS treatment

July 13, 2023
Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …

CellCentric announces $25m investment from Pfizer

July 12, 2023
Business Services Cancer, CellCentric, Oncology, Pfizer, collaboration, investment

UK-based biotechnology company CellCentric has announced a strategic investment from Pfizer including $25m to finance further development of inobrodib, its …

ADC Therapeutics puts clinical trial enrollment on hold following patient deaths

July 12, 2023
Medical Communications ADC Therapeutics, DLBCL, Oncology, clinical trial

ADC Therapeutics has announced a voluntary pause in the enrollment of patients for its phase 2 LOTIS-9 clinical trial which …

Virtual Inspections: Embracing the Digital Change

July 12, 2023
Manufacturing and Production ACG, Pharmacy, digital, manufacturing, virtual inspections

Virtual inspections must become a part of companies’ repertoires if they aim to maintain quality standards in their organisations. Digital …

Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial

July 11, 2023
Research and Development Innate Pharma, Oncology, Sanofi, clinical trial, multiple myeloma

Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase 1/2 clinical trial, which aims …

eye2

Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets

July 11, 2023
Research and Development 4D Molecular Therapeutics, AAV vectors, Astellas Pharma, Opthalmology, ophthalmology

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas has the right to use …

markus-spiske-dnbtfbnqlrc-unsplash_1

MHRA authorises GSK’s RSV vaccine for older adults

July 10, 2023
Medical Communications Arexvy, GSK, Infections and infestations, MHRA, RSV

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised its Arexvy respiratory syncytial virus (RSV) …

Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment

July 10, 2023
Sales and Marketing Cancer, Janssen, License Agreement, Oncology, nanobiotix

Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies …

The Gateway to Local Adoption Series

Latest content